Merck Mines Mevacor Switch Data To Press FDA On Self-Selection Stance
This article was originally published in The Pink Sheet Daily
Executive Summary
Purchase decisions in OTC switch self-selection studies offer insight into subjects’ thinking “and how they might act in a real-world pharmacy setting,” Merck tells FDA in response to a draft guidance that says such decisions are driven by cost and are “an unreliable surrogate” for self-selection.
You may also be interested in...
Self-Selection Studies Need Room To Evaluate Purchase Decisions – Expert
FDA should allow researchers more flexibility to evaluate consumers’ purchase decisions in self-selection studies for OTC drugs, according to contract research organization PEGUS Research.
FDA Advisors Say Greater Insight Needed On Self-Selection Of OTC Statins
More information from "real world" experiences on how consumers make OTC selections may be needed to pull off a successful Rx-to-OTC switch of a statin
NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.